Koers Evogene Ltd. TEL AVIV STOCK EXCHANGE
Aandelen
EVGN
IL0011050551
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 14,99 mln. 55,21 mln. 13,83 mln. | Omzet 2025 * | 25,85 mln. 95,2 mln. 23,85 mln. | Marktkapitalisatie | 33,16 mln. 122 mln. 30,6 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -22 mln. -81,02 mln. -20,3 mln. | Nettowinst (verlies) 2025 * | -19 mln. -69,97 mln. -17,53 mln. | EV/omzet 2024 * | 2,21 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 1,28 x |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,34% |
Recentste transcriptie over Evogene Ltd.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-01-02 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 01-04-22 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 01-01-05 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 17-11-21 |
Sarit Firon
CHM | Chairman | 58 | 11-08-16 |
Leon Recanati
BRD | Director/Board Member | 76 | 01-05-05 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+18,97% | 45,34 mld. | |
+41,98% | 40,42 mld. | |
-10,06% | 37,92 mld. | |
+31,15% | 31,75 mld. | |
-7,79% | 27,71 mld. | |
+13,32% | 26,52 mld. | |
+43,05% | 13,96 mld. | |
+31,28% | 12,44 mld. | |
-7,41% | 11,26 mld. |